

**SPECIALTY DRUG PROGRAM  
PRIOR AUTHORIZATION LIST**

The drugs on this list require prior authorization. Most of these drugs should be filled by a specialty pharmacy and are limited to a 30-day supply. **ConnectiCare’s preferred Specialty Pharmacy is Accredo.**


**\*\*\*Preferred Medications**

Call Pharmacy Services with specific questions:

**Members: 844-648-9625  
Physicians/Pharmacies: 866-759-1557  
Fax: 800-391-9707**

To see if a drug is on this list, browse the conditions and therapeutic class alphabetically. **Those medications that are obtained through a different provider are noted. This list may not be all-inclusive. New drugs will be added as approved by the FDA.**



You may also, use the search feature within your web browser by keying  on your keyboard.

Conditions/Class	Drug Names
Agents To Treat Multiple Sclerosis	Aubagio Avonex Bafiertam Betaseron Copaxone Dimethyl Gilenya Glatiramer Glatopa Kesimpta Lemtrada Mavenclad Mayzent Ocrevus Plegridy Ponvory Rebif Teriflunomide Vumerity
Agts Tx Neuromusc Transmission Dis;Pot-Chan Blkr	Dalfampridine

This list is subject to change and may not be all-inclusive.

[Back to Top](#)

New drugs will be added as approved by the U.S. Food and Drug Administration.

\* **Please note:** If the Search button does not work in the browser you are using, use the search feature within your web browser.

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Aminoglycoside Antibiotics	Bethkis Kitabis  Tobi Tobramycin
Amyloidosis Agents-Transthyretin (Ttr) Suppression	Tegsedi
Anticonvulsants	Vigabatrin Vigadrone
Antidiarrheal - Tryptophan Hydroxylase Inhibitor	Xermelo
Antifibrotic Therapy - Pyridone Analogs	Pirfenidone
Anti-Inflam. Interleukin-1 Receptor Antagonist	Arcalyst
Anti-Inflammatory Tumor Necrosis Factor Inhibitor	Adalimumab-Adaz(Cf) Amjevita(Cf) Cyltezo(Cf) Enbrel Humira Humira(Cf) Hyrimoz(Cf) Simponi
Anti-Inflammatory;Phosphodiesterase-4(Pde4) Inhib.	Otezla
Antileptotics	Thalomid
Anti-Narcolepsy;Anti-Cataplexy;Sedative-Type Agent	Lumryz Sodium Oxybate Xyrem Xywav
Antineoplast;Histone Deacetylase (Hdac) Inhibitors	Zolinza

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Antineoplastic - Antiandrogenic Agents	Abiraterone Erleada Nubeqa Xtandi Yonsa
Antineoplastic - Antimetabolites	Capecitabine Xeloda
Antineoplastic - Braf Kinase Inhibitors	Braftovi Tafinlar Zelboraf
Antineoplastic - Hedgehog Pathway Inhibitor	Daurismo Erivedge Odomzo
Antineoplastic - Janus Kinase (Jak) Inhibitors	Jakafi
Antineoplastic - Mek1 And Mek2 Kinase Inhibitors	Cotellic Mekinist Mektovi
Antineoplastic - Mtor Kinase Inhibitors	Everolimus
Antineoplastic Comb - Kinase And Aromatase Inhibit	Kisqali
Antineoplastic Immunomodulator Agents	Lenalidomide Revlimid
Antineoplastic Lhrh(Gnrh) Agonist;Pituitary Suppr.	Orgovyx

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Antineoplastic Systemic Enzyme Inhibitors	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>Alecensa</p> <p>Alunbrig</p> <p>Ayvakit</p> <p>Bosulif</p> <p>Cabometyx</p> <p>Calquence</p> <p>Caprelsa</p> <p>Cometriq</p> <p>Copiktra</p> <p>Erlotinib</p> <p>Exkivity</p> <p>Gavreto</p> <p>Gefitinib</p> <p>Gilotrif</p> <p>Ibrance</p> <p>Iclusig</p> <p>Imatinib</p> <p>Imbruvica</p> <p>Inlyta</p> <p>Iressa</p> <p>Kisqali</p> <p>Lapatinib</p> <p>Lenvima</p> <p>Lorbrena</p> <p>Lynparza</p> <p>Nexavar</p> <p>Ninlaro</p> <p>Pemazyre</p> <p>Retevmo</p> <p>Rozlytrek</p> <p>Rubraca</p> <p>Rydapt</p> <p>Scemblix</p> <p>Sorafenib</p> <p>Sprycel</p> <p>Stivarga</p> <p>Sunitinib</p> <p>Sutent</p> <p>Tagrisso</p> <p>Talzenna</p> <p>Tarceva</p> <p>Tasigna</p> <p>Tukysa</p> <p>Turalio</p> <p>Tykerb</p> <p>Verzenio</p> <p>Vitrakvi</p> <p>Vizimpro</p> </div> <div style="width: 45%;"> <p>Votrient</p> <p>Xalkori</p> <p>Xospata</p> <p>Zejula</p> <p>Zydelig</p> <p>Zykadia</p> <p>Vonjo</p> </div> </div>

This list is subject to change and may not be all-inclusive.  
 New drugs will be added as approved by the U.S. Food and Drug Administration.

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Antineoplastic-B Cell Lymphoma-2(Bcl-2) Inhibitors	Venclexta
Antineoplastic-Isocitrate Dehydrogenase Inhibitors	Idhifa
Antiparkinsonism Drugs;Other	Apomorphine Inbrija Nourianz Osmolex
Antipsoriatic Agents;Systemic	Skyrizi Taltz Tremfya
Antivirals; General	Livtencity
Arginine Vasopressin (Avp) Receptor Antagonists	Tolvaptan
Betalactams	Cayston
Bile Salts	Cholbam
Bone Formation Stim. Agents - Parathyroid Hormone	Forteo Teriparatide
Bone Formation Stimulating Agts - Pth Rel Peptides	Tymlos
Bone Resorption Inhibitors	Xgeva
Bradykinin B2 Receptor Antagonists	Icatibant Sajazir
C1 Esterase Inhibitors	Cinryze Haegarda Ruconest
Cardiac Myosin Inhibitor	Camzyos
Chemotherapy Rescue/Antidote Agents	Vistogard

This list is subject to change and may not be all-inclusive.  
 New drugs will be added as approved by the U.S. Food and Drug Administration.

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Cystic Fibrosis	Orkambi Symdeko Trikafta Kalydeco
Drugs To Treat Movement Disorders	Austedo Ingrezza Tetrabenazine
Farnesoid X Receptor (Fxr) Agonist; Bile Ac Analog	Ocaliva
Genetic D/O Tx - Smn Protein Deficiency Treatment	Evrysdi
Glucocorticoids	Tarpeyo
Glucosylceramide Synthase (Gcs) Inhibitor	Cerdelga Miglustat
Hepatitis C	Epclusa Harvoni Pegasys Viekira Vosevi Zepatier
Human Chorionic Gonadotropin (Hcg)	Chorionic Novarel Pregnyl
Human Interleukin 12/23 (Il-12/13) Inhibitors; Mab	Stelara
Hypnotics; Melatonin Mt1/Mt2 Receptor Agonists	Hetlioz Tasimelteon
Ileal Bile Acid Transporter (Ibat) Inhibitor	Bylvay
Immunomodulator;B-Lymphocyte Stim(Blys)-Spec Inhib	Benlysta

This list is subject to change and may not be all-inclusive.  
 New drugs will be added as approved by the U.S. Food and Drug Administration.

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Immunosuppressives	Lupkynis
Interleukin-13 (Il-13) Inhibitors; Mab	Adbry
Interleukin-4(Il-4) Receptor Alpha Antagonist; Mab	Dupixent
Interleukin-5 (Il-5) Antagonists; Mab	Nucala
Interleukin-5(Il-5) Receptor Alpha Antagonist; Mab	Fasenra
Interleukin-6 (Il-6) Receptor Inhibitors	Actemra
Janus Kinase (Jak) Inhibitors	Cibinqo Litfulo Rinvoq Xeljanz
Leukocyte (Wbc) Stimulants	Fulphila Ziextenzo
Leukocyte Adhesion Inhib;Alpha4-Mediat Igg4k Mc Ab	Tysabri
Monoclonal Antibodies To Immunoglobulin E (Ige)	Xolair
Pharmacological Chaperone-Alpha-Galactosid.A Stabz	Galafold
Pku Treatment Agents	Palynziq
Plasma Kallikrein Inhibitors	Kalbitor Orladeyo Takhzyro
Polycystic Kidney Disease Agent; Avp Recep. Antag	Jynarque

**SPECIALTY DRUG PROGRAM**  
**PRIOR AUTHORIZATION LIST**

Conditions/Class	Drug Names
Pulm Anti-Htn	Adempas Alyq Ambrisentan Bosentan Opsumit Orenitram Revatio Sildenafil Tadalafil Tracleer Uptravi
Pulmonary Fibrosis - Systemic Enzyme Inhibitors	Ofev
Pyruvate Kinase Activators	Pyrukynd
Rho Kinase Inhibitor	Rezurock
Selective Estrogen Receptor Modulators (Serms)	Orserdu
Selective Serotonin 5-Ht2a Inverse Agonists (Ssia)	Nuplazid
Somatostatic Agents	Mycapssa Somatuline
Sphingosine 1-Phosphate (S1p) Receptor Modulator	Zeposia
Spleen Tyrosine Kinase Inhibitors	Tavalisse
Systemic Enzyme Inhibitors	Joenja Vioice Zokinvy
Thrombopoietin Receptor Agonists	Doptelet